SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
171.25
-6.95 (-3.90%)
At close: 4:00PM EDT

171.25 0.00 (0.00%)
After hours: 4:33PM EDT

Stock chart is not supported by your current browser
Previous Close178.20
Open179.74
Bid169.95 x 800
Ask188.49 x 900
Day's Range170.02 - 181.19
52 Week Range79.88 - 185.60
Volume321,750
Avg. Volume432,709
Market Cap8.759B
Beta (3Y Monthly)2.97
PE Ratio (TTM)N/A
EPS (TTM)-9.79
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est201.33
Trade prices are not sourced from all markets
  • How a failed epilepsy drug became a $34,000 postpartum cure
    CNBC Videos2 months ago

    How a failed epilepsy drug became a $34,000 postpartum cure

    According to the Centers for Disease Control and Prevention, 1 in 9 women in the United States experience symptoms of postpartum depression. Looking at individual states, postpartum depression can affect as many as 1 in 5 women. In March 2019, the FDA approved the first postpartum depression drug, developed by Sage Therapeutics. Led by CEO Jeff Jonas, Sage Therapeutics created the treatment by taking a different approach toward mental health.

  • Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy?
    Insider Monkey7 days ago

    Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy?

    Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]

  • Business Wire9 days ago

    Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

    Sage Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 8:40 a.m. EST in New York, NY. A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

  • Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection
    Business Wire13 days ago

    Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection

    Sage Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Drug Enforcement Administration (DEA) has placed ZULRESSO™ (brexanolone) injection into Schedule IV of the Controlled Substances Act. ZULRESSO, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, is the first and only treatment specifically approved for postpartum depression (PPD), the most common medical complication of childbirth. With this decision, the product label for ZULRESSO will be finalized.

  • Business Wire22 days ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 3, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 4,200 shares of its common stock, and 700 performance restricted stock units (PSUs) to two new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • Business Wire23 days ago

    Sage Therapeutics to Present at Goldman Sachs 40th Annual Global Healthcare Conference

    Sage Therapeutics , a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 8:00 a.m.

  • GuruFocus.com29 days ago

    Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $15 million of Shares

    President & CEO of Sage Therapeutics Inc (NASDAQ:SAGE) Jeffrey M Jonas sold 85,736 shares of SAGE on 05/29/2019 at an average price of $174.78 a share.

  • PR Newswirelast month

    Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE

    LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare ...

  • Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%?
    Simply Wall St.last month

    Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%?

    How far off is Sage Therapeutics, Inc. (NASDAQ:SAGE) from its intrinsic value? Using the most recent financial data...

  • Ligand Grants Preclinical Candidate Rights to UK-based Firm
    Zackslast month

    Ligand Grants Preclinical Candidate Rights to UK-based Firm

    Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

  • Business Wirelast month

    Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference

    Sage Therapeutics , a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 2019 at 3:35 p.m.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT

    Q1 2019 SAGE Therapeutics Inc Earnings Call

  • American City Business Journals2 months ago

    New England Venture Capital Association names 2019 NEVY Awards winners

    The final winners are selected by the NEVYs Technology, Healthcare and Life Sciences Academies among a pool of nominees revealed in March. This year's seventh annual NEVYs marked the first time the Healthcare category had a dedicated Academy distinct from Life Sciences.

  • Small-Cap Stocks to Watch in May
    Motley Fool2 months ago

    Small-Cap Stocks to Watch in May

    These two companies are set to announce important business updates this month.

  • Business Wire2 months ago

    Sage Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference

    Sage Therapeutics , a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 8:40 a.m.

  • Markit2 months ago

    See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.

    SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for SAGE with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.47 billion over the last one-month into ETFs that hold SAGE are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire2 months ago

    Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress

    Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the first quarter ended March 31, 2019. “We started 2019 with positive data from a Phase 3 clinical trial of our lead oral compound SAGE-217 in postpartum depression and this was quickly followed by the FDA approval of ZULRESSO in PPD,” said Jeff Jonas, M.D., chief executive officer at Sage.

  • ACCESSWIRE2 months ago

    SAGE Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 2, 2019 / SAGE Therapeutics, Inc. (NASDAQ: SAGE ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:00 AM Eastern ...

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Sage Therapeutics, Inc.

    NEW YORK, April 29, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Sage Therapeutics, Inc. (NASDAQGM: SAGE) concerning possible breaches of.

  • Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community
    CNBC2 months ago

    Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community

    In June, Zulresso — the first and only medicine approved by the Food and Drug Administration to specifically treat postpartum depression — will hit the market. Sage Therapeutics, the maker of the drug, now hopes to win the fight against another major issue: The public's misconception about mental health.

  • Analysts point to potential Biogen M&A options after Alzheimer's failure
    American City Business Journals2 months ago

    Analysts point to potential Biogen M&A options after Alzheimer's failure

    Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.

  • Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • Business Wire2 months ago

    Sage Therapeutics to Report First Quarter 2019 Financial Results on Thursday, May 2, 2019

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 2, 2019 at 8:00 A.M. ET to report its first quarter 2019 financial results and to discuss recent business updates. The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.